What are ASCO/OH(CCO) recommendations for treating stage IV non–small cell lung cancer (NSCLC) in patients with ROS1 fusions?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print
Answer

First-line treatment

Any of the following may be offered:

  • Crizotinib
  • Entrectinib
  • Standard treatment for NSCLC without driver mutations
  • Ceritinib
  • Lorlatinib

Second-line treatment:

  • If ROS1-targeted therapy was given in the first-line setting, standard treatment for NSCLC without driver mutations should be offered
  • If nontargeted therapy was given in the first-line setting, crizotinib, ceritinib, or entrectinib may be offered

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!